Bambusa Therapeutics (BBTX) investor relations material

Company overview and business model

• Clinical-stage biopharma developing long-acting bispecific antibodies for immunology and inflammation, combining validated pathways in single molecules engineered for high-concentration subcutaneous delivery.

• Four programs: BBT001 targets IL-4Rα/IL-31; BBT002 IL-4Rα/IL-5; BBT003 TL1A/IL-23p19; BBT004 is a dual B-cell-depletion candidate.

• BBT001 and BBT002 are in clinical development; BBT003 is planned to enter the clinic by YE 2026 and BBT004 by YE 2027.

• Programs were sourced or developed with BioNTech Zhuhai; development, manufacturing, and clinical operations rely substantially on third parties.

Financial performance and metrics

• 6M 2026 R&D expense $20.6M vs $11.9M in 6M 2025; total operating expenses $24.1M vs $15.4M.

• 6M 2026 net loss $22.4M vs $14.7M in 6M 2025; FY 2025 net loss $41.1M vs $13.7M from inception through Dec. 31, 2024.

• Cash, cash equivalents and marketable securities totaled $71.5M at June 30, 2026; accumulated deficit was $77.2M.

• Management reported substantial doubt about going concern; June 30 resources were not expected to fund operations for at least 12 months from the financial-statement issuance date.

• Raised $136.1M gross through preferred-stock financings from inception through June 30, 2026; no product-sales revenue to date.

Use of proceeds and capital allocation

• Net IPO proceeds plus existing cash are intended primarily for BBT001 development, including the planned Phase 2b atopic dermatitis study, and BBT002 development, including a planned Phase 2b respiratory trial.

• Remaining proceeds are planned for R&D and clinical advancement of BBT003 and BBT004, capital expenditures, working capital, and public-company costs.

• Pending deployment, proceeds are planned for short-term investment-grade instruments, including AAA-rated money market funds, certificates of deposit, and U.S. government obligations.